申请人:HARVARD COLLEGE
公开号:WO2017142621A1
公开(公告)日:2017-08-24
Specific cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hERG activity, and/or other pharmacological properties which make them stand out among the class of cortistatins as superior candidates for human administration.
提供了具有有利特性的特定肾上腺皮质素衍生物,可供给需要的宿主,包括人类,在体内使用。这些新物种具有有利的药代动力学特性、低毒性、低至中等的hERG活性和/或其他药理特性,使它们在肾上腺皮质素类中脱颖而出,成为人类使用的优选候选物。